

**Bill History**  
**Session Year 2022**  
**Raised S.B. No. 188**

[Bill Analysis For File Copy 214](#)

[File No. 214 \[doc\]](#)

[Fiscal Note For File Copy 214](#)

[GL Joint Fav. Rpt](#)

[Raised Bill \[doc\]](#)

[GL Joint Favorable \[doc\]](#)

[GL Vote Tally Sheet \(Joint Favorable\)](#)

**Introducer(s):**

General Law Committee

**Title:** AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS.

**Statement of Purpose:** To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.

**Bill History:**

02-24-2022 REFERRED TO JOINT COMMITTEE ON General Law Committee

02-25-2022 PUBLIC HEARING 03/01

03-15-2022 JOINT FAVORABLE

03-16-2022 FILED WITH LEGISLATIVE COMMISSIONERS' OFFICE

03-24-2022 REFERRED TO OFFICE OF LEGISLATIVE RESEARCH AND OFFICE OF FISCAL ANALYSIS 03/29/22-5:00 PM

03-30-2022 REPORTED OUT OF LEGISLATIVE COMMISSIONERS' OFFICE

03-30-2022 FAVORABLE REPORT, TABLED FOR THE CALENDAR, SENATE

03-30-2022 SENATE CALENDAR NUMBER 170

03-30-2022 FILE NUMBER 214

04-07-2022 REFERRED BY SENATE TO COMMITTEE ON Judiciary Committee

**Co-sponsor(s):**

Sen. Martin M. Looney, 11th Dist.    Sen. Saud Anwar, 3rd Dist.

Rep. Michael A. Winkler, 56th Dist.